Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.37 |
| ▸ | BCR | P11274 | 3/20 | 0.37 |
| ▸ | GRM5 | P41594 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528127 | 0.77 | GRM5 (0.58) | GRM5MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL4529142 | 0.73 | GRM5 (0.47) | GRM5ALDH1A1 | |
| SCHEMBL5909238 | 0.71 | HPGD (0.64) | GABRA5ABL1BCRGRM5HPGD | |
| SCHEMBL4515095 | 0.71 | GRM5 (0.58) | GRM5 | |
| SCHEMBL990230 | 0.70 | GRM5 (0.74) | GRM5 | |
| SCHEMBL23231138 | 0.65 | HPGD (0.63) | GABRA5HPGD | |
| SCHEMBL12844641 | 0.64 | GABRA5 (0.48) | GABRA5GRM5HPGDALDH1A1HSD17B10 | |
| SCHEMBL12776443 | 0.64 | HPGD (0.49) | GABRA5GRM5HPGDMEN1KMT2A | |
| SCHEMBL990140 | 0.63 | GRM5 (0.80) | GRM5 | |
| SCHEMBL94847 | 0.62 | HPGD (0.56) | GRM5HPGDPKMALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005363-A1 | Organic Compounds | NNT, NAPRT, CHRNA5 | GABRA5 190/4885ABL1 2094/4885BCR 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.